0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > FGF R4

FGF R4

Brief Information

Name:Fibroblast growth factor receptor 4
Target Synonym:EC:2.7.10.1,Fibroblast growth factor receptor 4,CD334,FGFR4,TKF,JTK2,Tyrosine Kinase Related To Fibroblast Growth Factor Receptor,Hydroxyaryl-Protein Kinase,Protein-Tyrosine Kinase,Tyrosylprotein Kinase,CD334 Antigen,EC 2.7.10.1,FGFR-4,EC 2.7.10,Receptor,
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:10
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
FG4-H5253 Human Human FGF R4 / CD334 Protein, Fc Tag
FG4-H5253-structure
FG4-M52Ha Mouse Mouse FGF R4 / CD334 Protein, His Tag
FG4-M52Ha-structure
FG4-M52Ha-sds
FG4-M52Ha-elisa_1
FG4-H5228 Human Human FGF R4 / CD334 Protein, His Tag
FG4-H5228-structure
FG4-H5228-sds

Part of Bioactivity data

FG4-M52Ha-ELISA
Mouse FGF R4, His TagMouse FGF R4, His Tag (Cat. No. FG4-M52Ha) ELISA bioactivity

Immobilized Mouse FGF R4, His Tag (Cat. No. FG4-M52Ha) at 2 μg/mL (100 μL/well) can bind Human FGF-9, Fc Tag (Cat. No. FG9-H4267) with a linear range of 0.156-5 μg/mL (QC tested).

Synonym Name

FGFR4,CD334,JTK2,MGC20292,TKF

Background

Fibroblast growth factor receptor 4(FGFR4) is also known as CD334, JTK2,  hydroxyaryl-protein kinase, TKF, protein-tyrosine kinase . The FGFR4 gene provides instructions for making a protein called fibroblast growth factor receptor 4. This protein is part of a family of fibroblast growth factor receptors that share similar structures and functions. These receptor proteins play a role in important processes such as cell division, regulating cell growth and maturation, formation of blood vessels, wound healing, and embryo development.The FGFR4 protein interacts with specific growth factors to conduct signals from the environment outside the cell to the nucleus. The nucleus responds to these signals by switching on or off appropriate genes that help the cell adjust to changes in the environment. In response, the cell might divide, move, or mature to take on specialized functions. Although specific functions of FGFR4 remain unclear, studies indicate that the gene is involved in muscle development and the maturation of bone cells in the skull. The FGFR4 gene may also play a role in the development and maintenance of specialized cells (called foveal cones) in the light-sensitive layer (the retina) at the back of the eye.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Erdafitinib G-024; JNJ-493; 890E37NHMV; JNJ-42756493 Approved Astex Pharmaceuticals Inc Balversa United States Carcinoma, Transitional Cell Janssen Biotech Inc 2019-04-12 Solid tumours; Carcinoma; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Bile Duct Neoplasms; Urologic Neoplasms; Hepatic Insufficiency; Lymphoma; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung Details
Lenvatinib Mesylate ER-203492-00; E-7080 Approved Eisai Co Ltd Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 United States Endometrial Neoplasms Eisai Inc 2015-02-13 Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Gallbladder Neoplasms; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Cholangiocarcinoma; Sarcoma; Liver Diseases; Liver Neoplasms; Triple Negative Breast Neoplasms; Kidney Diseases; Small Cell Lung Carcinoma; Thyroid Carcinoma, Anaplastic; Adenocarcinoma of Lung; Esophageal Neoplasms; Renal Insufficiency; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Biliary Tract Neoplasms; Solid tumours Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
H3B-6527 H3B-6527 Phase 1 Clinical H3 Biomedicine Liver Neoplasms; Cholangiocarcinoma; Carcinoma, Hepatocellular Details
ICP-105 ICP-105 Phase 1 Clinical Beijing Tiancheng Pharmaceutical Technology Co Ltd, Nanjing Tianyin Jianhua Pharmaceutical Technology Co Ltd, Innocare Pharma Solid tumours; Liver Neoplasms Details
Aldafermin M-70; NGM-282 Phase 2 Clinical Ngm Biopharmaceuticals Liver Cirrhosis, Biliary; Constipation; Non-alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 2; Renal Insufficiency; Fibrosis; Cholangitis, Sclerosing; Hepatic Insufficiency; Diabetes Mellitus Details
BPI-43487 BPI-43487 Phase 1 Clinical Betta Pharmaceuticals Co Ltd Biliary Tract Neoplasms; Solid tumours; Carcinoma, Hepatocellular Details
Fisogatinib BLU-554; CS-3008 Phase 2 Clinical Blueprint Medicines Corp Carcinoma, Hepatocellular Details
ABSK-011 ABSK-011 Phase 1 Clinical Abbisko Therapeutics Liver Neoplasms; Solid tumours Details
Roblitinib FGF-401; NVP-FGF401 Phase 2 Clinical Novartis Pharma Ag Solid tumours; Neoplasms; Carcinoma, Hepatocellular Details
LY-2874455 LY-2874455 Phase 2 Clinical Eli Lilly And Company Neoplasms Details
PRN-1371 PRN-1371 Phase 1 Clinical Principia Biopharma Inc Solid tumours; Urinary Bladder Neoplasms Details
Futibatinib TAS-120 Phase 3 Clinical Otsuka Pharmaceutical Co Ltd, Taiho Pharmaceutical Co Ltd Bone Marrow Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma; Carcinoma, Transitional Cell; Brain Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung Details
SY-4798 Phase 1 Clinical Shouyao Holding (Beijing) Co Ltd Solid tumours Details

This web search service is supported by Google Inc.

totop